drugset / Trial / NCT00670566

Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients

NCT00670566

Phase 4 Completed 503 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective is to evaluate the antihypertensive efficacy of a fixed combination of Irbesartan/HydroChloroThiazide (CoAprovel) in Chinese moderate to severe hypertensive patients. The secondary objective is to get systolic blood pressure and diastolic blood pressure goal attainment rate from CoAprovel in Chinese hypertensive patients.

Timeline

Start
2008-04
Primary completion
2009-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrochlorothiazide Unknown 25 mg
Subject Irbesartan Small molecule 300 mg

Indications